Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Audentes Therapeutics Inc (BOLD)

Audentes Therapeutics Inc (BOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,774,932
  • Shares Outstanding, K 46,272
  • Annual Sales, $ 0 K
  • Annual Income, $ -128,820 K
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.14
  • Most Recent Earnings -1.00 on 11/07/19
  • Next Earnings Date 02/26/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.01
  • Number of Estimates 8
  • High Estimate -0.89
  • Low Estimate -1.07
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -20.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.27 +1.18%
on 12/16/19
60.00 -0.05%
on 01/06/20
+0.57 (+0.96%)
since 12/13/19
3-Month
25.41 +136.01%
on 11/18/19
60.00 -0.05%
on 01/06/20
+32.56 (+118.79%)
since 10/14/19
52-Week
22.00 +172.59%
on 01/29/19
60.00 -0.05%
on 01/06/20
+35.15 (+141.62%)
since 01/14/19

Most Recent Stories

More News
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion

Encoded Therapeutics, Inc. (Encoded), a precision gene therapy company, today announced the appointment of Salvador Rico, M.D., Ph.D., as chief medical officer and the promotion of Martin Moorhead, Ph.D.,...

BOLD : 59.97 (-0.02%)
Astellas Completes Acquisition of Audentes Therapeutics

Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has successfully completed the previously announced acquisition of Audentes...

ALPMF : 17.6500 (-1.40%)
BOLD : 59.97 (-0.02%)
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

AMAG : 8.91 (+0.34%)
EBS : 63.17 (+0.27%)
AMRN : 17.62 (-0.40%)
BOLD : 59.97 (-0.02%)
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

EBS : 63.17 (+0.27%)
AGEN : 3.66 (unch)
GILD : 67.56 (+1.14%)
BOLD : 59.97 (-0.02%)
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

PFE : 36.51 (-1.14%)
SGEN : 118.07 (-0.13%)
ALPMY : 17.2500 (-1.03%)
BOLD : 59.97 (-0.02%)
Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone...

RHHBY : 43.3900 (-0.66%)
SRPT : 125.42 (+0.31%)
SLDB : 3.17 (-0.94%)
BOLD : 59.97 (-0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - BOLD, INST, THOR

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

BOLD : 59.97 (-0.02%)
INST : 47.66 (+3.70%)
THOR : 67.99 (unch)
TECD, TIF, BOLD, and WLH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

BOLD : 59.97 (-0.02%)
TECD : 144.05 (+0.02%)
TIF : 134.27 (-0.07%)
WLH : 24.37 (+2.57%)
AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Audentes Therapeutics, Inc. (NASDAQ:BOLD) breached their fiduciary...

ALPMF : 17.6500 (-1.40%)
BOLD : 59.97 (-0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - BOLD, AKS, INST, THOR

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

BOLD : 59.97 (-0.02%)
AKS : 2.94 (-3.29%)
INST : 47.66 (+3.70%)
THOR : 67.99 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BOLD with:

Business Summary

Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for...

See More

Key Turning Points

2nd Resistance Point 60.00
1st Resistance Point 59.98
Last Price 59.97
1st Support Level 59.96
2nd Support Level 59.96

See More

52-Week High 60.00
Last Price 59.97
Fibonacci 61.8% 45.48
Fibonacci 50% 41.00
Fibonacci 38.2% 36.52
52-Week Low 22.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar